Alymsys Injection, Solution
Product Images NDC 85006-1755

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alymsys (NDC 85006-1755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Valorum Biologics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alymsys Bevacizumab Maly Injection 1)

Figure 1 (Alymsys Bevacizumab Maly Injection 1)
This text appears to be a comparison between two treatment groups (IFL + Placebo and IFL + Bevacizumab) over a period of time (0, 6, 12, 18 months). It includes the number of patients at risk in each group at different time points. The data seems to be related to a medical or clinical study evaluating the effectiveness of these treatments.*
FDA Label Image

Valorum-400mg Carton (Alymsys Bevacizumab Maly Injection 10)

Valorum-400mg Carton (Alymsys Bevacizumab Maly Injection 10)
This description includes details about a pharmaceutical product called Alymsys. It is an injection containing bevacizumab-maly, with a concentration of 400 mg/16 mL (25 mg/mL). The product is for intravenous infusion and must be diluted before use. Each mL contains specific components, and the product must be stored refrigerated at 2°C to 8°C. It comes in a single-dose vial and should be discarded if unused. The manufacturer is Amneal Pharmaceuticals LLC, and it is distributed by Valorum Biologics, LLG. The product is a prescription medication and is a product of Spain with a US License No. 2241. The Universal Code for the product is also provided in the text.*
FDA Label Image

Figure 2 (Alymsys Bevacizumab Maly Injection 2)

Figure 2 (Alymsys Bevacizumab Maly Injection 2)
FDA Label Image

Figure 3 (Alymsys Bevacizumab Maly Injection 3)

Figure 3 (Alymsys Bevacizumab Maly Injection 3)
This is not a readable text.*
FDA Label Image

Figure 4 (Alymsys Bevacizumab Maly Injection 4)

Figure 4 (Alymsys Bevacizumab Maly Injection 4)
FDA Label Image

Figure 5 (Alymsys Bevacizumab Maly Injection 5)

Figure 5 (Alymsys Bevacizumab Maly Injection 5)
FDA Label Image

Figure 6 (Alymsys Bevacizumab Maly Injection 6)

Figure 6 (Alymsys Bevacizumab Maly Injection 6)
FDA Label Image

Valorum-100mg Label (Alymsys Bevacizumab Maly Injection 7)

Valorum-100mg Label (Alymsys Bevacizumab Maly Injection 7)
FDA Label Image

Valorum-100mg Carton (Alymsys Bevacizumab Maly Injection 8)

Valorum-100mg Carton (Alymsys Bevacizumab Maly Injection 8)
The text provides information about a medication called Alymsys, which is a preservative-free bevacizumab solution packaged in a single-dose vial. Each milliliter contains 25 mg of bevacizumab to be diluted for intravenous infusion. The medication should be refrigerated between 2°C to 8°C and protected from light. The distributor is Valorum Biologics, LLC, and the manufacturer is Amneal Pharmaceuticals LLC based in Bridgewater, NJ. The National Drug Code (NDC) for Alymsys is 85006-1754-1. It is crucial to follow prescription instructions and to discard any unused portion of the medication.*
FDA Label Image

Valorum-400mg Label (Alymsys Bevacizumab Maly Injection 9)

Valorum-400mg Label (Alymsys Bevacizumab Maly Injection 9)
This product is a medication with the NDC 85006-1755-1 code. It is meant to be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. It is advised not to freeze or shake the medication. The dosage information can be found in the prescribing information. The medication is to be diluted in 0.9% Sodium Chloride Injection, USP before intravenous infusion. Unused portions should be discarded.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.